Navigation Links
Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results Teleconference and Webcast
Date:2/12/2009

EMERYVILLE, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will webcast a teleconference with management to provide an update on Nexavar(R) (sorafenib) tablets, as well as to discuss fourth quarter and full year 2008 financial results, on Monday, February 23, 2009, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Financial results for the fourth quarter and year ended December 31, 2008 will be released earlier that day.

Interested parties may access a live webcast of the presentation on the company's website at: http://www.onyx-pharm.com/wt/page/event_calendar or by dialing 847-413-3238 and using the passcode 23828951. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 23828951 approximately one hour after the teleconference concludes. The replay will be available through March 23, 2009.

New Presentation of Statement of Operations

In December 2007, the Financial Accounting Standards Board (FASB) ratified Emerging Issues Task Force (EITF) 07-1, "Accounting for Collaborative Arrangements". Onyx has elected to adopt this new accounting guidance as of December 31, 2008, and as a result, the company's Statement of Operations for the year ending December 31, 2008 will be reported under this new presentation. This new presentation changes the classification of amounts included in specific lines in the Statement of Operations, but does not change net income (loss) or net income (loss) per share.

Under this new presentation, the Statement of Operations includes the line item "Revenue from Collaboration Agreement." This line item consists of Onyx's share of the commercial profit generated from the collaboration with Bayer, reimbursement of Onyx's shared marketing costs related to Nexavar and Nexavar royalty revenue. Onyx's 50% share of collaboration research and development expenses is included in the research and development expense line item.

In addition, all prior periods from January 1, 2006 through September 30, 2008 will be reclassified to conform to this new guidance and will be presented in Onyx's Form 8-K to be filed with the Securities and Exchange Commission prior to the fourth quarter and full year 2008 financial results call on February 23, 2009. For additional information on the structure of the company's new Statement of Operations, please visit the investor section of Onyx's website at http://www.onyx-pharm.com/wt/page/investors.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R), a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other cancers. For more information about Onyx, visit the company's website at http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Union Springs Pharmaceuticals Introduces New, More Effective Respirator
2. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter and Full-Year 2008 Financial Results
3. DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease
4. Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel
5. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
6. Biotest Pharmaceuticals Corporation Acquires Santa Fe, New Mexico Plasmapheresis Center
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Par Pharmaceutical Announces Outcome of the Litigation With Pentech Pharmaceuticals
9. Mpex Pharmaceuticals Announces Series D Financing of Up to $40 Million
10. Prism Pharmaceuticals Study of Injectable Clopidogrel Accepted for Presentation at the American College of Cardiology
11. Genesis Pharmaceuticals Successfully Defends Itself in a Multi-Million Dollar Arbitration, Two Other Arbitration Proceedings Against Genesis are Withdrawn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Bioclinica® ... sponsors and CROs to speed clinical development, has released the industry’s only ... Bioclinica AGILE RTSM provides seamless clinical supply forecasting and management together ...
(Date:4/25/2017)... KY (PRWEB) , ... April 25, 2017 , ... ... announce they have signed an agreement to be the preferred physical therapy provider ... injuries and returning them to Derby City CrossFit as quickly and effectively as ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report from the ... for the 2015-16 school year across Wisconsin’s public schools, charter schools, and private ... patterns in student test score performance, the report’s limited analyses fail to provide ...
(Date:4/25/2017)... ... 2017 , ... As pharmaceutical companies are held to increasingly ... innovation in drug formulation and manufacturing. CoreRx offers its clients more than ... support of their development and manufacturing goals. , The company was created ...
(Date:4/25/2017)... Scotch Plains, NJ (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD ... with the treatment of acute or chronic problems, I focus on preventative care with all ... patient. If you have any questions, always feel free to contact my office and my ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 Global Surgical Drainage Device ... tubes used to remove excess liquid and air. The ... urine, bile or lymph. Surgical drains are used in ... as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. ... to prevent accumulation of fluid e.g. blood or pus. ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group ... it is developing at Conejo Spectrum Business Park ... to Atara Biotherapeutics, Inc. , a biopharmaceutical ... and life-threatening diseases that have been underserved by ... T-cell therapies for cancer, autoimmune and infectious disease. ...
Breaking Medicine Technology: